9th Annual Biomarkers Congress

Patrys Awarded Grant for Lead Clinical Candidate

Patrys Limited (ASX: PAB), a leader in the development of novel and safe treatments for cancers with high mortality rates, announced today that scientific collaborators at the University of Melbourne have been awarded a $300,000 grant to support the development of Patrys' lead clinical candidate PAT-SM6.

PAT-SM6 is a natural human antibody that has shown great promise for the treatment of solid tumours and metastases in a number of cancer applications, including melanoma, pancreatic cancer and gastric cancer.

A first-in-human clinical trial for PAT-SM6 is scheduled for this calendar year.

http://www.patrys.com/mediareleases.php



Comments

POSTED:2012-01-15 18:41:05

AUTHOR: GUEST

TslYuK , [url=http://oklnprzdtcbv.com/]oklnprzdtcbv[/url], [link=http://xtxvfcqybsbb.com/]xtxvfcqybsbb[/link], http://otckvqwfosdm.com/


POSTED:2012-01-14 09:48:13

AUTHOR: GUEST

3LjHMr <a href="http://rilgnilmygdz.com/">rilgnilmygdz</a>


POSTED:2012-01-11 13:40:48

AUTHOR: GUEST

uImbgj <a href="http://xebtvlejxbeu.com/">xebtvlejxbeu</a>


POSTED:2012-01-11 00:40:31

AUTHOR: GUEST

I cannot tell a lie, that rellay helped.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.